Paid Clinical Trials Thousand Oaks
Discover 2,973 paid clinical trials in Thousand Oaks, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT05552976
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Mezigdomide
Carfilzomib
Dexamethasone
CLN-619 & PembrolizumabA Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Sponsor:
Cullinan Therapeutics Inc.
Location:
Code:
NCT05117476
Conditions
Advanced Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CLN-619
Pembrolizumab
CenerimodA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Sponsor:
Idorsia Pharmaceuticals Ltd.
Location:
Code:
NCT05672576
Conditions
Lupus Erythematosus, Systemic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Cenerimod
Placebo
LY3541860A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06859294
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
LY3541860
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
LuspaterceptA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Sponsor:
Celgene
Location:
Code:
NCT04064060
Conditions
Myelodysplastic Syndromes (MDS)
Beta-thalassemia
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Luspatercept
Pembrolizumab & ATL-DCPembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Sponsor:
Jonsson Comprehensive Cancer Center
Location:
Code:
NCT04201873
Conditions
Recurrent Glioblastoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dendritic Cell Tumor Cell Lysate Vaccine
Pembrolizumab
Placebo Administration
Poly ICLC
Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor:
Allogene Therapeutics
Location:
Code:
NCT06500273
Conditions
Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemacabtagene ansegedleucel
ALLO-647
Fludarabine
Cyclophosphamide
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Topical AgentsComparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
Sponsor:
City of Hope Medical Center
Location:
Code:
NCT05340673
Conditions
Breast Ductal Carcinoma In Situ
Invasive Breast Carcinoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Agent Affecting Integumentary System
Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment
Quality-of-Life Assessment
Questionnaire Administration